Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006

Abstract We tested the in vitro activity of 15 antimicrobials against Gram-positive cocci and 12 antimicrobials against Gram-negative bacilli versus 3931 isolates (20 most common organisms) obtained between September 1, 2005, and June 30, 2006, from 19 intensive care units (ICUs) across Canada. The...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostic microbiology and infectious disease 2008-09, Vol.62 (1), p.67-80
Main Authors: Zhanel, George G, DeCorby, Mel, Nichol, Kim A, Wierzbowski, Aleksandra, Baudry, Patricia J, Karlowsky, James A, Lagacé-Wiens, Philippe, Walkty, Andrew, Mulvey, Michael R, Hoban, Daryl J
Format: Article
Language:English
Subjects:
Acinetobacter baumannii
Anti-Bacterial Agents - pharmacology
Biological and medical sciences
Canada
Drug Resistance, Bacterial
Escherichia coli
Fundamental and applied biological sciences. Psychology
Gram-Negative Bacteria - drug effects
Gram-Negative Bacteria - isolation & purification
Gram-Negative Bacterial Infections - microbiology
Gram-Positive Bacterial Infections - microbiology
Gram-Positive Cocci - drug effects
Gram-Positive Cocci - isolation & purification
Humans
Infectious Disease
Infectious diseases
Intensive care units
Intensive Care Units - statistics & numerical data
Internal Medicine
Medical sciences
Microbial Sensitivity Tests
Microbiology
Population Surveillance - methods
Pseudomonas aeruginosa
Resistance
Staphylococcus aureus
Staphylococcus epidermidis
Stenotrophomonas maltophilia
Susceptibility
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We tested the in vitro activity of 15 antimicrobials against Gram-positive cocci and 12 antimicrobials against Gram-negative bacilli versus 3931 isolates (20 most common organisms) obtained between September 1, 2005, and June 30, 2006, from 19 intensive care units (ICUs) across Canada. The most active (based upon MIC only) agents against methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis were dalbavancin, daptomycin, linezolid, tigecycline, and vancomycin with MIC90 (μg/mL) of 0.06 and ≤0.03, 0.25 and 0.12, 2 and 1, 0.5 and 0.5, and 1 and 2, respectively. The most active agents against vancomycin-resistant enterococci were daptomycin, linezolid, and tigecycline with MIC90 (μg/mL) of 1, 4, and 0.12, respectively. The most active agents against Escherichia coli were amikacin, cefepime, meropenem, piperacillin/tazobactam, and tigecycline with MIC90 (μg/mL) of 4, ≤1, ≤0.12, 8, and 0.5, respectively. The most active agents against extended-spectrum β-lactamase–producing E. coli were meropenem and tigecycline with MIC90 (μg/mL) of ≤0.12 and 1, respectively. The most active agents against Pseudomonas aeruginosa were amikacin, cefepime, meropenem, and piperacillin/tazobactam with MIC90 (μg/mL) of 16, 32, 16, and 64, respectively. The most active agents against Stenotrophomonas maltophilia were tigecycline and trimethoprim/sulfamethoxazole with MIC90 (μg/mL) of 4 and 4, respectively. The most active agents against Acinetobacter baumannii were fluoroquinolones (e.g., levofloxacin), meropenem, and tigecycline with MIC90 (μg/mL) of 0.5, 1, and 2, respectively. In conclusion, the most active agents versus Gram-positive cocci and Gram-negative bacilli obtained from Canadian ICUs were daptomycin, linezolid, tigecycline, dalbavancin and amikacin, cefepime, meropenem, piperacillin/tazobactam, and tigecycline (not P. aeruginosa ), respectively.
ISSN:0732-8893
1879-0070
DOI:10.1016/j.diagmicrobio.2008.04.012